{"success":true,"data":{"pressRelease":{"id":"3975","rtpr_id":"nPn9r0Cxba","ticker":"NKTR","exchange":"NASDAQ","all_tickers":["NKTR"],"title":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit","author":"PR Newswire","published_at":"2026-04-22T05:27:00.025Z","article_body":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit\n\nPR Newswire\n\nNEW YORK, April 22, 2026\n\nNEW YORK, April 22, 2026 /PRNewswire/ --\n\n(https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.html)\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\nsecurities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and\nDecember 15, 2025, both dates inclusive (the \"Class Period\"), of the important\nMay 5, 2026 lead plaintiff deadline.\n\nSo what: If you purchased Nektar securities during the Class Period you may be\nentitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWhat to do next: To join the Nektar class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55599\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2744546055&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599)\nor call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com) for information on the class\naction. A class action lawsuit has already been filed. If you wish to serve as\nlead plaintiff, you must move the Court no later than May 5, 2026. A lead\nplaintiff is a representative party acting on behalf of other class members in\ndirecting the litigation.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually handle securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many\nof the firm's attorneys have been recognized by Lawdragon and Super Lawyers.\n\nDetails of the case: According to the lawsuit, defendants made false and/or\nmisleading statements and/or failed to disclose that: (1) enrollment in the\nREZOLVE-AA trial had not followed applicable instructions and protocol\nstandards; (2) the foregoing was likely to have a significant negative impact\non the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's\noverall integrity and prospects were overstated; and (4) as a result,\ndefendants' public statements were materially false and misleading at all\nrelevant times. When the true details entered the market, the lawsuit claims\nthat investors suffered damages.\n\nTo join the Nektar class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55599\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2744546055&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599)\nor call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com) for information on the class\naction.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2545539265&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2916979349&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\nor on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=1575001016&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n     Laurence Rosen, Esq.\n     Phillip Kim, Esq.\n     The Rosen Law Firm, P.A.\n     275 Madison Avenue, 40th Floor\n     New York, NY 10016\n     Tel: (212) 686-1060\n     Toll Free: (866) 767-3653\n     Fax: (212) 202-3827\n     case@rosenlegal.com (mailto:case@rosenlegal.com)\n     www.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=3225023833&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-302749572.html\n(https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-302749572.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9r0Cxba","title":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit","author":"PR Newswire","ticker":"NKTR","created":"2026-04-22T05:27:00.025Z","tickers":["NKTR"],"exchange":"NASDAQ","article_body":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit\n\nPR Newswire\n\nNEW YORK, April 22, 2026\n\nNEW YORK, April 22, 2026 /PRNewswire/ --\n\n(https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.html)\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\nsecurities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and\nDecember 15, 2025, both dates inclusive (the \"Class Period\"), of the important\nMay 5, 2026 lead plaintiff deadline.\n\nSo what: If you purchased Nektar securities during the Class Period you may be\nentitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWhat to do next: To join the Nektar class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55599\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2744546055&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599)\nor call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com) for information on the class\naction. A class action lawsuit has already been filed. If you wish to serve as\nlead plaintiff, you must move the Court no later than May 5, 2026. A lead\nplaintiff is a representative party acting on behalf of other class members in\ndirecting the litigation.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually handle securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many\nof the firm's attorneys have been recognized by Lawdragon and Super Lawyers.\n\nDetails of the case: According to the lawsuit, defendants made false and/or\nmisleading statements and/or failed to disclose that: (1) enrollment in the\nREZOLVE-AA trial had not followed applicable instructions and protocol\nstandards; (2) the foregoing was likely to have a significant negative impact\non the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's\noverall integrity and prospects were overstated; and (4) as a result,\ndefendants' public statements were materially false and misleading at all\nrelevant times. When the true details entered the market, the lawsuit claims\nthat investors suffered damages.\n\nTo join the Nektar class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=55599\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2744546055&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D55599)\nor call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com) for information on the class\naction.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2545539265&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=2916979349&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\nor on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=1575001016&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n     Laurence Rosen, Esq.\n     Phillip Kim, Esq.\n     The Rosen Law Firm, P.A.\n     275 Madison Avenue, 40th Floor\n     New York, NY 10016\n     Tel: (212) 686-1060\n     Toll Free: (866) 767-3653\n     Fax: (212) 202-3827\n     case@rosenlegal.com (mailto:case@rosenlegal.com)\n     www.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670455-1&h=3225023833&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-302749572.html\n(https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-302749572.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-22T05:27:00.087969786Z","server_sent_at_ms":1776835620087},"received_at":"2026-04-22T05:27:00.145Z","source_url":null},"analysis":{"id":"2769","press_release_id":"3975","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Securities fraud lawsuit filed alleging clinical trial protocol violations","Allegations that REZOLVE-AA trial integrity was overstated"],"eventType":"legal_litigation","narrative":"The Rosen Law Firm announced a securities fraud class action lawsuit against Nektar Therapeutics regarding alleged misstatements about its REZOLVE-AA trial.\n\nThe lawsuit claims defendants failed to disclose that trial enrollment did not follow protocol standards, overstating the trial's integrity and prospects.\n\nInvestors who purchased securities between February 26, 2025 and December 15, 2025 have until May 5, 2026 to seek lead plaintiff status.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Securities fraud suit targets Nektar over REZOLVE-AA trial protocol allegations."},"keyFigures":{"customDimensions":{"class_period_end":"December 15, 2025","class_period_start":"February 26, 2025","lead_plaintiff_deadline":"May 5, 2026"}},"quotedText":"According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards","namedEntities":{"people":[{"name":"Laurence Rosen","role":"Founding Partner"},{"name":"Phillip Kim","role":"Attorney"}],"products":["REZOLVE-AA"],"companies":[{"name":"Nektar Therapeutics","ticker":"NKTR"},{"name":"The Rosen Law Firm, P.A.","relationship":"plaintiff counsel"}],"dollarAmounts":[{"amount":"$438 million","context":"amount secured for investors by the firm in 2019"}]},"materialImpact":{"score":4,"reasoning":"Securities fraud lawsuit alleging false statements regarding clinical trial protocol and integrity. This involves the company's core clinical assets (REZOLVE-AA) and carries significant financial and reputational risk."},"tickerRelevance":{"others":[],"primary":"NKTR"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"The Rosen Law Firm announced a securities fraud class action lawsuit against Nektar Therapeutics regarding alleged misstatements about its REZOLVE-AA trial.\n\nThe lawsuit claims defendants failed to disclose that trial enrollment did not follow protocol standards, overstating the trial's integrity and prospects.\n\nInvestors who purchased securities between February 26, 2025 and December 15, 2025 have until May 5, 2026 to seek lead plaintiff status.","key_figures":{"customDimensions":{"class_period_end":"December 15, 2025","class_period_start":"February 26, 2025","lead_plaintiff_deadline":"May 5, 2026"}},"named_entities":{"people":[{"name":"Laurence Rosen","role":"Founding Partner"},{"name":"Phillip Kim","role":"Attorney"}],"products":["REZOLVE-AA"],"companies":[{"name":"Nektar Therapeutics","ticker":"NKTR"},{"name":"The Rosen Law Firm, P.A.","relationship":"plaintiff counsel"}],"dollarAmounts":[{"amount":"$438 million","context":"amount secured for investors by the firm in 2019"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T05:29:58.638Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.854Z"}},"durationMs":177474,"modelName":"glm-4.7"}}